Skip to main content
. Author manuscript; available in PMC: 2022 May 8.
Published in final edited form as: Nat Cancer. 2021 Nov 8;2(11):1136–1151. doi: 10.1038/s43018-021-00267-9

Extended Data Fig. 3. BACE1 Is Highly Expressed by pTAMs in GBM Xenografts.

Extended Data Fig. 3

a,b, Immunofluorescent analyses of BACE1 and the pan TAM marker IBA1 or CD11b in GBM xenografts derived from GSCs (CCF-3264 or CCF-DI315). Representative immunofluorescent images (a) show the distribution and co-localization of BACE1 (in green) with the pan TAM marker (IBA1 or CD11b; in red) in GBM xenografts. Quantifications (b) show the fractions of BACE1-positive TAMs (BACE1+/IBA1+ or BACE1+/CD11b+ cells) in total TAMs (IBA1+ or CD11b+ cells) in GBM xenografts. Data are shown as means ± SEM. n = 6 GBM xenografts per group.

c,d, Immunofluorescent analyses of BACE1 and the pTAM marker CD163 or FIZZ1 in GBM xenografts derived from GSCs (CCF-3264 or CCF-DI315). Representative immunofluorescent images (c) show the distribution and co-localization of BACE1 (in green) with pTAM markers (CD163 and FIZZ1; in red) in GBM xenografts. Quantification (d) shows the fractions of BACE1-positive pTAMs (BACE1+/CD163+ or BACE1+/FIZZ1+ cells) in total pTAMs (CD163+ or FIZZ1+ cells) in GBM xenografts. Data are shown as means ± SEM. n = 6 GBM xenografts per group.

e,f, Immunofluorescent analyses of BACE1 and the sTAM marker HLA-DR or CD11c in GBM xenografts derived from GSCs (CCF-3264 or CCF-DI315). Representative immunofluorescent images (e) show staining of BACE1 (in green) and the sTAM markers (HLA-DR or CD11c; in red) in GBM xenografts. Quantification (f) shows the fractions of BACE1+ sTAMs (BACE1+HLA-DR+ or BACE1+CD11c+ cells) in total sTAMs (HLA-DR+ or CD11c+ cells) in GBM xenografts. Data are shown as means ± SEM. n = 6 GBM xenografts per group.